Corvus Pharmaceuticals, Inc. (CRVS) Reaches $8.23 After 5.00% Up Move; Shorts at Inflarx NV (IFRX) Lowered By 1.44%

February 13, 2018 - By Pete Kolinski

Inflarx NV (NASDAQ:IFRX) had a decrease of 1.44% in short interest. IFRX’s SI was 95,900 shares in February as released by FINRA. Its down 1.44% from 97,300 shares previously. With 28,500 avg volume, 3 days are for Inflarx NV (NASDAQ:IFRX)’s short sellers to cover IFRX’s short positions. The stock increased 12.87% or $3.54 during the last trading session, reaching $31.05. About 41,863 shares traded. InflaRx N.V. (NASDAQ:IFRX) has 0.00% since February 13, 2017 and is . It has underperformed by 16.70% the S&P500.

The stock of Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) is a huge mover today! The stock increased 4.05% or $0.32 during the last trading session, reaching $8.23. About 67,784 shares traded. Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) has declined 11.61% since February 13, 2017 and is downtrending. It has underperformed by 28.31% the S&P500.The move comes after 7 months positive chart setup for the $173.17 million company. It was reported on Feb, 13 by Barchart.com. We have $8.64 PT which if reached, will make NASDAQ:CRVS worth $8.66M more.

InflaRx GmbH, a clinical-stage biopharmaceutical company, focuses on discovering and developing inhibitors using C5a technology in the United States. The company has market cap of $726.91 million. The Company’s C5a is an inflammatory mediator involved in the enhancement of a variety of autoimmune and other inflammatory diseases. It currently has negative earnings. The firm is involved developing IFX-1, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; ANCA-associated vasculitis, a rare and life-threatening autoimmune disease; and other chronic/autoimmune diseases, as well as IFX-2 for the treatment of chronic inflammation and autoimmune diseases.

Analysts await Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) to report earnings on March, 9. They expect $-0.66 earnings per share, down 20.00% or $0.11 from last year’s $-0.55 per share. After $-0.62 actual earnings per share reported by Corvus Pharmaceuticals, Inc. for the previous quarter, Wall Street now forecasts 6.45% negative EPS growth.

Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of novel immuno-oncology therapies that are designed to harness the immune system to attack cancer cells. The company has market cap of $173.17 million. The Company’s lead product candidate is CPI-444, an oral, small molecule antagonist of the A2A receptor that is in Phase I/Ib clinical trial for adenosine, an immune checkpoint. It currently has negative earnings. The firm is also developing an anti-CD73 monoclonal antibody that inhibits the production of adenosine; an antagonist of the adenosine A2B receptor; and small molecule covalent inhibitors of interleukin-2 inducible kinase.

- Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


>